Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Zymeworks Inc.

Zymeworks ( ($ZYME) ) has issued an announcement. Zymeworks has received U.S. FDA Fast Track designation for ZW191, an antibody-drug conjugate targ...

Zymeworks Wins FDA Fast Track Status for Ovarian Cancer Drug ZW191

Zymeworks ( ($ZYME) ) has provided an update. Zymeworks will showcase new clinical and preclinical data from its antibody-drug conjugate portfolio,...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ZYME	$26.81	+3.10%	389.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ZYME	$26.81	+3.1%	389.23K
3
4
5
6

ZYME

ZYME

No Data Available

Get Zymeworks Inc. Data in Excel

Get Zymeworks Inc. Data in Excel